Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.31%
|
$9,000
$15.01 P/Share
|
|
Sep 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,833
-8.7%
|
$1,183,300
$100.52 P/Share
|
|
Sep 15
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+18.71%
|
$577,500
$66.24 P/Share
|
|
Sep 13
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-0.37%
|
$99,000
$99.27 P/Share
|
|
Sep 13
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Sep 13
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
600
-5.61%
|
$60,000
$100.0 P/Share
|
|
Sep 13
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.31%
|
$9,000
$15.01 P/Share
|
|
Aug 26
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+7.83%
|
$16,000
$1.87 P/Share
|
|
Aug 19
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
25,000
-6.54%
|
$2,300,000
$92.61 P/Share
|
|
Aug 19
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.07%
|
$200,000
$8.44 P/Share
|
|
Aug 17
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,350
-11.79%
|
$122,850
$91.93 P/Share
|
|
Aug 17
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,350
+5.73%
|
$6,750
$5.34 P/Share
|
|
Jul 13
2021
|
George Demetri |
BUY
Open market or private purchase
|
Direct |
10
+0.17%
|
$820
$82.66 P/Share
|
|
Jun 28
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-0.61%
|
$90,000
$90.02 P/Share
|
|
Jun 28
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Jun 02
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,292
-4.23%
|
$114,988
$89.03 P/Share
|
|
Jun 02
2021
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+5.37%
|
-
|
|
Jun 02
2021
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+3.26%
|
-
|
|
Jun 02
2021
|
Lynn Seely |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Charles A Rowland Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
George Demetri |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Lonnel Coats |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 02
2021
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+27.91%
|
-
|
|
Jun 01
2021
|
Percy H. Carter CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,843
+50.0%
|
-
|
|
Jun 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
237
-2.29%
|
$21,567
$91.67 P/Share
|
|
May 17
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
3,055
-23.23%
|
$290,225
$95.0 P/Share
|
|
May 17
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,350
+5.01%
|
$6,750
$5.34 P/Share
|
|
May 12
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
25,000
-4.36%
|
$2,300,000
$92.61 P/Share
|
|
May 12
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.07%
|
$200,000
$8.44 P/Share
|
|
Mar 15
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-0.37%
|
$106,000
$106.46 P/Share
|
|
Mar 15
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Mar 04
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
18,986
-1.28%
|
$1,689,754
$89.65 P/Share
|
|
Mar 04
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.96%
|
$80,000
$8.8 P/Share
|
|
Mar 04
2021
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
1,359
-2.06%
|
$118,233
$87.86 P/Share
|
|
Mar 04
2021
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
1,210
-3.02%
|
$105,270
$87.81 P/Share
|
|
Mar 04
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,893
-2.73%
|
$164,691
$87.81 P/Share
|
|
Mar 04
2021
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,507
-2.49%
|
$131,109
$87.8 P/Share
|
|
Mar 04
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,952
-1.75%
|
$169,824
$87.85 P/Share
|
|
Mar 04
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
1,693
-2.61%
|
$147,291
$87.79 P/Share
|
|
Mar 04
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
857
-3.4%
|
$74,559
$87.92 P/Share
|
|
Mar 03
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
515
-3.91%
|
$50,470
$98.45 P/Share
|
|
Mar 01
2021
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+22.28%
|
-
|
|
Mar 01
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+29.94%
|
-
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,700
-11.43%
|
$168,300
$99.51 P/Share
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+5.37%
|
$8,500
$5.34 P/Share
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,187
+19.48%
|
-
|
|
Mar 01
2021
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+23.72%
|
-
|
|
Mar 01
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+28.63%
|
-
|
|
Mar 01
2021
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+30.05%
|
-
|
|
Mar 01
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+27.32%
|
-
|